This prospective investigation identifies neoadjuvant chemotherapy response using PIV in HER2-positive breast cancer, highlighting its potential as a predictive biomarker.
Key Points
PIV was significantly associated with pathological response in locally advanced breast cancer patients.
Of 168 patients, 88.9% of those achieving pCR had low PIV compared to 78.8% with high PIV among nonresponders.
Patients received standard anthracycline-taxane–based NACT, and analysis utilized SPSS v30 for statistical validation.
Finding a PIV cutoff at 543.51 suggests this marker may optimize individualized treatment strategies for LABC.